Cost-effectiveness analysis of the administration of palivizumab as prophylaxis of severe bronchiolitis due to respiratory syncytial virus;Anàlisi cost-efectivitat de l'administració del palivizumab en la profilaxi de les bronquiolitis greus per virus respiratori sincicial

Pediatria Catalana

Volumn 70, Issue 2, 2010, Pages 57-64

  García Altés, Anna ^a,b,c   Paladio, Núria ^c,d   Tebé, Cristian ^c,d   Pons, Joan M V ^c,d  

^a Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^b AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d Agència d Avaluació de Tecnologia i Recerca Mèdiques   (Spain)

Author keywords

Bronchiolitis; Cost effectiveness analysis; Palivizumab; Prophilactic administration

Indexed keywords

PALIVIZUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; LIFE EXPECTANCY; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SENSITIVITY ANALYSIS; VIRAL BRONCHIOLITIS;

EID: 77957684759     PISSN: 11358831     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118: 1.774-1.793.
2. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003; 143: 118-126.
3. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143: 112-117.
4. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001; 183: 16-22.
5. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Technical Report. Pediatrics 2003; 112: 1.447-1.452.
6. Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004; 23: 193-201.
7. Esperanza de vida al nacimiento. Indicadores demográficos básicos. Mortalidad 2005 [pàgina a Internet]. Madrid: Instituto Nacional de Estadística. Disponible a: http://www.ine.es.
8. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154: 55-61.
9. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood M, et al. La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España. An Pediatr (Barc) 2006; 65: 316-324.
10. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540.
11. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419-427. (Pubitemid 29424659)
12. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 2004; 114: 1.612-1.619.
13. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102: 531-537.
14. Coste-efectividad de palivizumab en la prevención de la hospitalización por virus respiratorio sincitial en prematuros de 32 a 35 semanas de gestación. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Consejería de Salud; 2006. Informe 5/2006.
15. Drummond MF, O'Brien B, Stoddart G, Torrance GW. Methods for the economic evaluation of health care programmes (2a ed.). Oxford: Oxford University Press, 1997.
16. Sacristan JA, Oliva J, Del LJ, Prieto L, Pinto JL. What is an efficient health technology in Spain? Gac Sanit 2002; 16: 334-343.
17. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis R) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. A West Midlands Development and Evaluation Service Report. Birmingham (United Kingdom): Department of Public Health and Epidemiology. University of Birmingham, 2001.
18. Fariña D, Rodríguez SP, Bauer G, Novali L, Bouzas L, González H, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J 2002; 21: 287-291.
19. Lapeña S, Robles MB, Martínez JP, Castañón L, Mallo J, Herrero B, et al. Impacto potencial y análisis coste-eficacia de la profilaxis con palivizumab, en la prevención de bronquiolitis, en prematuros menores de 33 semanas de gestación. An Pediatr (Barc) 2003; 59: 328-333.
20. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114: 1.606-1.111.
21. Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006; 42: 253-258. (Pubitemid 43736361)
22. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects-hospitalizations and costs. Acta Paediatr 2006; 95: 404-406. (Pubitemid 43739064)
23. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006; 160: 1.070-1.076.
24. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007; 25: 55-71. (Pubitemid 46072368)
25. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003; 22: 823-827. (Pubitemid 37153079)
26. Carbonell-Estrany X. Palivizumab outcomes registry data from Spain: Infeccion Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group. Pediatr Infect Dis J 2003; 22(2 Suppl): 55-57.
27. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001; 35: 1.186-1.193.
28. Resch B, Gusenleitner W, Muller WD, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 2006; 25: 120-122. (Pubitemid 43333675)
29. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162: 237-244. (Pubitemid 36437756)
30. Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 2005; 90: 64-68.
31. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 2002; 96 Suppl B: S1-S7. (Pubitemid 39665384)
32. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137: 865-870.